Doxepin hydrochloride Property

Melting point:

187-189°C

Flash point:

9℃

storage temp. 

2-8°C

solubility 

1 M HCl: 50 mg/mL

form 

powder

color 

white to off-white

Water Solubility 

Soluble in water (100 mM), chloroform (1:2), alcohol (1:1), methanol, and DMSO.

λmax

298nm(lit.)

Merck 

14,3435

Stability:

Store in Freezer at -20°C

InChIKey

MHNSPTUQQIYJOT-SJDTYFKWSA-N

CAS DataBase Reference

1229-29-4(CAS DataBase Reference)

Safety

Hazard Codes 

T,F

Risk Statements 

25-39/23/24/25-23/24/25-11

Safety Statements 

36/37/39-45-36/37-16

RIDADR 

UN 2811 6.1/PG 3

WGK Germany 

3

RTECS 

HQ4375000

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

29329990

Toxicity

LD50 oral in rat: 147mg/kg

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

Doxepin hydrochloride Chemical Properties,Usage,Production

Description

Doxepin is a tricyclic antidepressant that binds to the serotonin (5-HT) transporter (SERT) and norepinephrine transporter (NET; K_ds = 68 and 29.5 nM, respectively). It is a histamine H₁ receptor antagonist (K_i = 1.23 nM). Doxepin selectively binds to SERT and NET over the dopamine transporter (DAT; K_d = 12,100 nM) and inhibits histamine H₁ over H₂, H₃, and H₄ receptors (K_is = 170, 39,810, and 15,135 nM, respectively). It also binds to the 5-HT₂ receptor, as well as to muscarinic acetylcholine and α₁-adrenergic receptors (α₁-ARs; K_ds = 27, 23, and 23.5 nM, respectively). Doxepin (10 mg/kg, i.p.) decreases allodynia and hyperalgesia in a mouse model of chronic constriction injury-induced neuropathic pain. It increases the distance traveled in the center of the open field test and reduces immobility time in the forced swim test in a mouse model of depression induced by chronic stress when administered orally at a dose of 15 mg/kg. Formulations containing doxepin have been used in the treatment of depression and insomnia.

Chemical Properties

White Solid

Originator

Sinequan,Pfizer,US,1969

Uses

Doxepin is used clinically to treat anxiety and depression. Doxepin is an antidepressant.

Uses

Used clinically to treat anxiety and depression. Antidepressant.

Uses

Doxepin hydrochloride is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine and acts as an antagonist at histamine, serotonin, adrenergic, and muscarinic receptors with Ki values in the nanomolar range.It is a antidepressant used clinically to treat anxiety and depression.

Definition

ChEBI: Doxepin Hydrochloride is a dibenzooxazepine.

Indications

Doxepin (Sinequan, Adapin) is a tricyclic antidepressant with potent H1 and H2 antagonistic effects. It also has antimuscarinic, antiserotonic, and anti-α-adrenergic activity. Use of 10 to 50 mg PO t.i.d. to q.i.d. has been shown to be effective in the treatment of primary acquired, chronic idiopathic urticaria, idiopathic cold urticaria, and for patients with anxiety or depression associated with their urticaria. Sedation and dry mouth are the most common side effects. Doxepin may interact with other drugs that are metabolized by the cytochrome P-450 system (ketoconazole, itraconazole, erythromycin, clarithromycin, etc.).

Manufacturing Process

(A) Preparation of 3-bromopropyltriphenylphosphonium bromide: Triphenylphosphine, 1.0 kg, and 770 grams of 1,3-dibromopropane are dissolved in 2.0 liters of xylene and the solution is stirred under a nitrogen atmosphere at 130°C. After 20 hours the mixture is cooled, and the crystalline product, which precipitates, is collected and washed with 20 liters of benzene. After drying in vacuo the product weighs 1,578 grams, MP 229°-230°C;titration for bromide ion: Found, 17.1%; calculated, 17.2%.
(B) Preparation of 3-dimethylaminopropyltriphenylphosphonium bromide hydrobromide: A solution of 595 grams of anhydrous dimethylamine and 1,358 grams of 3-bromopropyl-triphenylphosphonium bromide in 4 liters of ethanol is warmed to 70°C until solution is complete and the solution then is allowed to stand at room temperature for 20 hours. Volatile components are removed by distillation in a vacuum and the residue is suspended in 2.0 liters of ethanol and is redistilled to remove excess amine. The residue is dissolved in 3.0 liters of warm ethanol and gaseous hydrogen bromide is passed into the solution until the mixture is acidic. After filtration the solution is concentrated to a volume of 3.0 liters, is cooled, whereupon the product precipitates, and the precipitate is collected; it weighs 1,265 grams, MP 274- 281°C. Recrystallization from ethanol raises the MP to 280.5°-282.5°C. Bromide ion titration: Found, 31.2%; calculated 31.3%.
(C) Preparation of doxepin: 1,530 grams of the product from step (B) is suspended in 4.5 liters dry tetrahydrofuran and 6.0 mols of butyl lithium in heptane is added during 1 hour. After an additional 30 minutes, 483 grams of 6,11-dihydrodibenz-(b,e)oxepin-11-one, prepared as described in Belgian Patent 641,498, is added to the deep red solution and the reaction was maintained at reflux for 10 hours. Water, 500 ml, is added at room temperature and the solvent is removed in vacuo. The crude residue is treated with 10% hydrochloric acid until acidic (pH 2) and then 1.5 liters benzene is added. After stirring, the mixture separates into 3 phases (an insoluble hydrochloride salt product phase, an aqueous phase and an organic phase).
The benzene layer is removed by decantation and the remaining mixture is rendered basic with 10% sodium hydroxide solution and is extracted with three 1,500 ml portions of benzene. The benzene extracts are washed, then dried with anhydrous sodium sulfate and concentrated in a vacuum leaving a residue of 1,530 grams, gas and thin layer chromatography analysis show this to be a cis/trans mixture (approx. 4:l) of 11-dimethylaminopropylidene-6,11- dihydrodibenz-(b,e)oxepin (90% yield). This mixture has substantially more activity pharmacologically than the cis/trans mixture obtained by the Grignard route disclosed in the Belgian Patent 641,498. This base is then converted to the hydrochloride with HCl.

brand name

Sinequan (Pfizer); Zonalon (Bradley).

Therapeutic Function

Tranquilizer

General Description

Doxepin, 3-dibenz[b,e]-oxepin-11(6H)ylidine-N,N-dimethyl-1-propanamine hydrochloride, N,N-dimethyl-3-(dibenz[b,e]oxepin-11(6H)-ylidene)propylamine (Sinequan, Adapin), isan oxa congener of amitriptyline, as can be seen from itsstructure.
The oxygen is interestingly placed and should influenceoxidative metabolism as well as postsynaptic and presynapticbinding affinities. The (Z)-isomer is the more active, althoughthe drug is marketed as the mixture of isomers. Thedrug overall is a NE and 5-HT reuptake blocker with significantanticholinergic and sedative properties. It can be anticipatedthat the nor- or des- metabolite will contribute to theoverall activity pattern.

Biochem/physiol Actions

Tricyclic antidepressant that is a more potent inhibitor of norepinephrine uptake than of serotonin uptake; antagonist at H1 histamine, muscarinic cholinergic, and α-adrenoreceptors.

Veterinary Drugs and Treatments

The primary use for doxepin in veterinary medicine is the adjunctive therapy of psychogenic dermatoses, particularly those that have an anxiety component. Its efficacy as an antihistamine for atopic dermatoses is in question.

in vitro

doxepin was a moderately potent competitive inhibitor of serotonin uptake in human blood platelets in vitro, with an inhibitory constant ki of ～0.2 μm. doxepin (100 μm) rapidly increased the efflux of serotonin from platelets [1].

in vivo

in rats and dog, oral administration of doxepin was well absorbed and quickly appeared in the blood. numerous metabolites of doxepin were observed in liver and in urine, only doxepin and demethyl doxepin were found in the rat brain[3]..

References

[1] lingjrde o. effect of doxepin on uptake and efflux of serotonin in human blood patelets in vitro[j]. psychopharmacology, 1976, 47(2): 183-186.
[2] hill s j, ganellin c r, timmerman h, et al. international union of pharmacology. xiii. classification of histamine receptors[j]. pharmacological reviews, 1997, 49(3): 253-278.
[3] hobbs d c. distribution and metabolism of doxepin[j]. biochemical pharmacology, 1969, 18(8): 1941-1954.
[4] hajak g, rodenbeck a, voderholzer u, et al. doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study[j]. journal of clinical psychiatry, 2001, 62(6): 453-463.
[5] feighner j p, cohn j b. double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder[j]. the journal of clinical psychiatry, 1985, 46(3 pt 2): 20-25.
[6] goldsobel a b, rohr a s, siegel s c, et al. efficacy of doxepin in the treatment of chronic idiopathic urticaria[j]. journal of allergy and clinical immunology, 1986, 78(5): 867-873.